Q: What is Spevigo used for?

Spevigo is used to treat generalized pustular psoriasis flares.

Q: How does Spevigo work?

Mechanism of Action Spevigo (spesolimab-sbzo) belongs to a class of drugs called monoclonal antibodies. It works by targeting and binding to the interleukin-36 (IL-36) receptor, a protein found on the surface of various immune cells. In a healthy immune system, the IL-36 pathway helps the body respond to perceived threats. However, in people with generalized pustular psoriasis (GPP), this pathway becomes overactive. This overstimulation triggers a cascade of inflammation and causes the body to send too many white blood cells, known as neutrophils, to the skin. How It Reduces Symptoms By blocking the IL-36 receptor, Spevigo prevents inflammatory signals from being delivered. This action helps to: Stop the inflammatory cycle: It prevents IL-36 proteins from activating the receptor, which slows down the immune system's overreaction. Reduce skin damage: By limiting the accumulation of neutrophils, it helps decrease the formation of painful, pus-filled blisters and skin redness. Manage flares: The medication is designed to address the underlying cause of GPP symptoms during an active flare or to help prevent future flares.

Q: What are the active ingredients in Spevigo?

The active ingredient in Spevigo is spesolimab .

Q: What are the side effects of Spevigo?

Common side effects of Spevigo may include: infusion reactions fatigue headache Always consult with a healthcare professional about potential side effects.

Q: What drug class is Spevigo?

Spevigo belongs to the interleukin-36 receptor antagonist drug class.

Q: What is the dosage of Spevigo and how do I take it?

Administration Methods Spevigo is given in two different ways depending on the treatment goal: Intravenous Infusion: To treat an active flare of generalized pustular psoriasis, the medication is typically given by a healthcare professional through a needle into a vein. This procedure is performed in a clinical setting such as a doctor's office or hospital. Subcutaneous Injection: To help prevent future flares, the medication is injected under the skin of the abdomen or thighs. Self-Injection Instructions If you are using the subcutaneous injection for prevention, your healthcare provider will provide training on how to prepare and inject the medication at home. Do not attempt to self-inject until you have been properly trained. Before use, the medication should be removed from the refrigerator and allowed to reach room temperature naturally. Do not shake the medication, and check to ensure the liquid is clear to slightly yellow before injecting. Missed Dose If you miss a scheduled dose of the subcutaneous injection, contact your healthcare provider for guidance on when to administer your next dose. Do not use extra medication to make up for a missed dose.

Q: Is Spevigo safe during pregnancy and breastfeeding?

Pregnancy Data on the use of Spevigo in pregnant women are limited, and there is not enough evidence to determine if the medication increases the risk of birth defects, miscarriage, or other developmental issues. Because Spevigo is a monoclonal antibody, it is expected to cross the placental barrier and may be transmitted from the mother to the developing fetus. Individuals who are pregnant or planning to become pregnant should discuss the potential benefits and risks of treatment with their healthcare provider. Breastfeeding It is currently unknown if Spevigo passes into human breast milk, how it might affect a nursing infant, or if it impacts the production of breast milk. While other similar antibodies are known to be present in human milk, specific studies on Spevigo have not been conducted. When deciding whether to breastfeed while using this medication, it is important to consider the mother's clinical need for the drug alongside the potential risks to the infant and the benefits of breastfeeding.

Q: What is the FDA approval status of Spevigo?

FDA Approval History Spevigo (spesolimab-sbzo) received its initial FDA approval in September 2022 for the treatment of generalized pustular psoriasis (GPP) flares in adults. In March 2024, the FDA expanded this approval to include the treatment of GPP in adults and pediatric patients aged 12 and older (weighing at least 40 kg) to prevent flares. Approved Indications The FDA has approved Spevigo for the following uses: Treatment of GPP flares in adults (administered intravenously). Treatment of GPP in adults and pediatric patients 12 years of age and older weighing at least 40 kg (administered subcutaneously). Regulatory Safety Information The FDA has not issued a boxed warning for Spevigo, and there is no Risk Evaluation and Mitigation Strategy (REMS) required for its use. Regulatory labeling includes precautions for the following: Infections: Spevigo may increase the risk of infections. Treatment should not be started in patients with a clinically important active infection. Hypersensitivity: Serious hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported. Immunizations: Patients should avoid receiving live vaccines while being treated with Spevigo. Tuberculosis: Patients should be evaluated for tuberculosis infection prior to starting therapy.

Question 1

What is Spevigo?

Accepted Answer

Spevigo is a monoclonal antibody that acts as an interleukin-36 receptor antagonist. It works by binding to the interleukin-36 receptor, which is a part of the immune system involved in signaling inflammation.

By blocking this receptor, the medication prevents the activation of specific pathways that contribute to inflammatory responses in the body. This mechanism helps to regulate the immune system's activity.

Question 2

What is Spevigo used for?

Accepted Answer

Spevigo is used to treat generalized pustular psoriasis flares.

Question 3

How does Spevigo work?

Accepted Answer

Mechanism of Action

Spevigo (spesolimab-sbzo) belongs to a class of drugs called monoclonal antibodies. It works by targeting and binding to the interleukin-36 (IL-36) receptor, a protein found on the surface of various immune cells.

In a healthy immune system, the IL-36 pathway helps the body respond to perceived threats. However, in people with generalized pustular psoriasis (GPP), this pathway becomes overactive. This overstimulation triggers a cascade of inflammation and causes the body to send too many white blood cells, known as neutrophils, to the skin.

How It Reduces Symptoms

By blocking the IL-36 receptor, Spevigo prevents inflammatory signals from being delivered. This action helps to:

Stop the inflammatory cycle: It prevents IL-36 proteins from activating the receptor, which slows down the immune system's overreaction.
Reduce skin damage: By limiting the accumulation of neutrophils, it helps decrease the formation of painful, pus-filled blisters and skin redness.
Manage flares: The medication is designed to address the underlying cause of GPP symptoms during an active flare or to help prevent future flares.

Question 4

What are the active ingredients in Spevigo?

Accepted Answer

The active ingredient in Spevigo is spesolimab.

Question 5

What are the side effects of Spevigo?

Accepted Answer

Common side effects of Spevigo may include:

infusion reactions
fatigue
headache

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Spevigo?

Accepted Answer

Spevigo belongs to the interleukin-36 receptor antagonist drug class.

Question 7

What is the dosage of Spevigo and how do I take it?

Accepted Answer

Administration Methods

Spevigo is given in two different ways depending on the treatment goal:

Intravenous Infusion: To treat an active flare of generalized pustular psoriasis, the medication is typically given by a healthcare professional through a needle into a vein. This procedure is performed in a clinical setting such as a doctor's office or hospital.
Subcutaneous Injection: To help prevent future flares, the medication is injected under the skin of the abdomen or thighs.

Self-Injection Instructions

If you are using the subcutaneous injection for prevention, your healthcare provider will provide training on how to prepare and inject the medication at home. Do not attempt to self-inject until you have been properly trained. Before use, the medication should be removed from the refrigerator and allowed to reach room temperature naturally. Do not shake the medication, and check to ensure the liquid is clear to slightly yellow before injecting.

Missed Dose

If you miss a scheduled dose of the subcutaneous injection, contact your healthcare provider for guidance on when to administer your next dose. Do not use extra medication to make up for a missed dose.

Question 8

Is Spevigo safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Data on the use of Spevigo in pregnant women are limited, and there is not enough evidence to determine if the medication increases the risk of birth defects, miscarriage, or other developmental issues. Because Spevigo is a monoclonal antibody, it is expected to cross the placental barrier and may be transmitted from the mother to the developing fetus.

Individuals who are pregnant or planning to become pregnant should discuss the potential benefits and risks of treatment with their healthcare provider.

Breastfeeding

It is currently unknown if Spevigo passes into human breast milk, how it might affect a nursing infant, or if it impacts the production of breast milk. While other similar antibodies are known to be present in human milk, specific studies on Spevigo have not been conducted.

When deciding whether to breastfeed while using this medication, it is important to consider the mother's clinical need for the drug alongside the potential risks to the infant and the benefits of breastfeeding.

Question 9

What forms and strengths does Spevigo come in?

Accepted Answer

Spevigo is supplied as a sterile, preservative-free solution in the following forms:

Injection for Intravenous Infusion: This form is provided in a single-dose vial and is administered into a vein by a healthcare professional.
Injection for Subcutaneous Use: This form is provided in a single-dose prefilled syringe for injection under the skin.

Question 10

What is the FDA approval status of Spevigo?

Accepted Answer

FDA Approval History

Spevigo (spesolimab-sbzo) received its initial FDA approval in September 2022 for the treatment of generalized pustular psoriasis (GPP) flares in adults. In March 2024, the FDA expanded this approval to include the treatment of GPP in adults and pediatric patients aged 12 and older (weighing at least 40 kg) to prevent flares.

Approved Indications

The FDA has approved Spevigo for the following uses:

Treatment of GPP flares in adults (administered intravenously).
Treatment of GPP in adults and pediatric patients 12 years of age and older weighing at least 40 kg (administered subcutaneously).

Regulatory Safety Information

The FDA has not issued a boxed warning for Spevigo, and there is no Risk Evaluation and Mitigation Strategy (REMS) required for its use. Regulatory labeling includes precautions for the following:

Infections: Spevigo may increase the risk of infections. Treatment should not be started in patients with a clinically important active infection.
Hypersensitivity: Serious hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported.
Immunizations: Patients should avoid receiving live vaccines while being treated with Spevigo.
Tuberculosis: Patients should be evaluated for tuberculosis infection prior to starting therapy.

Question 11

What should I know about Spevigo and cost?

Accepted Answer

Factors Affecting Cost

The price of Spevigo can vary significantly based on several factors:

Insurance Plan: Your out-of-pocket costs, such as copays or coinsurance, are determined by your specific health insurance provider and pharmacy benefit tier.
Administration Site: Costs may differ depending on whether the medication is administered in a hospital, an outpatient clinic, or at home.
Treatment Type: Spevigo is available as an intravenous infusion for flares and as a subcutaneous injection for maintenance, which may be billed differently under medical or pharmacy benefits.

Financial Assistance

Because Spevigo is a specialized biologic medication, the manufacturer may offer support programs. These can include co-pay savings cards for commercially insured patients or patient assistance programs for those who are uninsured or underinsured. Eligibility for these programs is typically based on income and insurance status.

Generic Availability

There is currently no generic or biosimilar version of Spevigo available. It is a brand-name medication, which generally means it has a higher cost than generic alternatives.

Prior Authorization

Most insurance companies require prior authorization for Spevigo. This process requires your healthcare provider to submit documentation to your insurer to confirm the medication is medically necessary before coverage is approved.

Spevigo

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Spevigo

Hospitals.net Disclosure